Technology has evolved over the years, and so have online websites and apps. Growing food delivery apps are the newest trend, expanding revenue generation in the food-service industry by 22% or more. And this new trend has created an even greater opportunity beyond food delivery alone!
Uber Eats has about 20% of the market, while GrubHub, including Seamless and Eat24, has 52%. In its latest funding effort, DoorDash raised $250 million after the five-year-old San Francisco-based startup raised $535 million in March. Furthermore, DoorDash, which competes with GrubHub (GRUB), Uber Eats, and Postmates, has raised nearly $1 billion overall.
CEO of Uber Dara Khosrowshahi has said that Uber Eats is growing at 200% per year and has a $6 billion run rate, meaning that it’s on track to book $6 billion over the next 12 months given current rates. She said, “Going forward, we’re deliberately investing in the future of our platform: big bets like Uber Eats…”
Going Global – The Real Opportunity For Investors
Chinese investor and WeChat owner Tencent has joined a global lineup of investors seeking to write the biggest check in India’s food-technology sector for Swiggy. The online food-delivery platform has held discussions with a host of investors to raise $500-700 million, a significant portion of which Tencent wants to contribute, according to people familiar with the talks.
The investment could value Swiggy at $2.5-3 billion. Swiggy has also been in talks with Japan’s SoftBank for a sizeable investment since November, according to reports.
Another app called Rappi is a Colombian on-demand delivery startup that has brought in a new round of funding at a valuation north of $1 billion, as first reported by Axios and confirmed to TechCrunch by a source close to the company. DST Global led the more than $200 million in financing with participation from Andreessen Horowitz and Sequoia, all of which were existing investors in the company.
But Here’s The Problem: Most Companies Are Private
Private companies are mostly driving these billions and trillions of dollars that are being poured into this new On-Demand Economy. The average retail investor has little opportunity to take advantage of it, especially considering this idea of global expansion that could turbo-charge industry growth.
ParcelPal (PTNYF) (PKG) Is The One Company That’s Already Breaking Into The Global On-Demand Industry At A Rapid Pace
The opportunity that ParcelPal (PTNYF) (PKG) may be presenting now draws comparisons to the way early investors had an opportunity with companies like Uber and GrubHub (GRUB) before they went mainstream in the US. GrubHub priced its initial public offering at $26 per share and now trades nearly 5x that price just as this market is beginning to heat up!
The difference withParcelPal (PTNYF) (PKG) is that it is going directly after the international markets that have very limited access to technology like this right now. In fact, the major players in the industry are just beginning to get their feet wet with beta testing; they aren’t even full speed yet.
ParcelPal (PTNYF) (PKG) created an on-demand marketplace where customers can shop for anything from food to clothes. There is no more waiting in line for lunch or rushing to the store after work to grab your clothes. With ParcelPal on-demand, customers simply shop from the app, choose the items they want, and pay.
It’s true that new markets are difficult to enter, especially if it is a brand new way of doing business, such as the on-demand economy. But unlike the Ubers and Postmates in their early years, ParcelPal (PTNYF) (PKG) has already aligned with one of the largest online juggernauts in the history of the modern world.
ParcelPal (PTNYF) (PKG) has engaged in a work order contract with Amazon.com Inc. to fulfill package delivery on behalf of Amazon to residents in Metro Vancouver, British Columbia, Canada. ParcelPal (PTNYF) (PKG) has already seen exceptional growth in this division of the company since launch, growing over 115% week over week, delivering approximately 150,000 packages since mid-November.
The company is currently maintaining an average of 99%+ delivery success rate and is delivering thousands of packages daily on behalf of Amazon. The contract signed involves delivering for Amazon “Core” services. This entails delivering Amazon merchandise to Greater Vancouver residents.
The company is already aiming to expand on both the existing “Core” business and Amazon Prime services!
Entry Into Key Verticals
Something that is beginning to set ParcelPal (PTNYF) (PKG) apart from its immediate competition is its diversification strategy. Not only is the company working with the likes of Amazon, but it is also entering into key verticals that are seeing an increase in rapid demand. Right now, ParcelPal has built relationships with businesses in both alcohol and cannabis.
We don’t have to go into the deep details of these booming industries, but it is vital to understand that the evolution from brick-and-mortar to on-demand delivery could be setting the stage for a major economic boom.
While consumers are becoming more comfortable with using smartphones and computers to buy groceries, they are also increasingly using the same technology to help them skip trips to the liquor store, according to data from the e-commerce analytics firm, Slice Intelligence.
Online alcohol sales of beer, liquor, and wine grew 32.7% in 2017, according to Slice. By far, the most popular kind of adult beverage bought on the Web is wine, which represented more than 65% of online alcohol sales during the 25-month period from Jan. 1, 2016 to Jan. 31, 2018, according to Slice. Spirits follow that, at 21.2%, and beer at 13.8%.
“While e-commerce in the alcoholic beverage space is still immature, we are starting to see the shape of a robust category,” says Ken Cassar, principal analyst for Slice. “It makes sense that wine would lead all subcategories within alcoholic beverages, due to the relatively high value of scarce wine. Ultimately, though, beer will likely win as grocers figure out how to manage through complicated laws that vary by local jurisdiction.”
This is just one slice of ParcelPal (PTNYF) (PKG)’s directive to take on “sin-dustries” (sin industries like alcohol, tobacco, and marijuana). With the budding market in Canada alone proposed to reach somewhere in the billions of dollars, cannabis presents a more near-term opportunity for ParcelPal.
According to the latest projections from San Francisco-based ArcView Group, a marijuana research, and investment firm, in partnership with Boulder-based BDS Analytics, a cannabis-focused market researcher, the Canadian legal cannabis sector is estimated to generate $1.3 billion in 2018. By 2022, the forecast is even more robust—$5.4 billion for both the medical and recreational markets.
ParcelPal Strategically Advances Into Marijuana Space Through Acquisition and Partnership with TokeIt Technologies
ParcelPal (PTNYF) (PKG) has entered into a definitive agreement for partial acquisition and exclusive partnership with marijuana seed-to-sale provider and online ordering system, TokeIt Technologies, Inc.
A cannabis focus will give all TokeIt-engaged licensed dispensaries the ability to offer their consumers the opportunity to order marijuana directly through the ParcelPal or TokeIt applications and have it delivered in an hour or less. This partnership offers ParcelPal access to thousands of customers in neighborhoods throughout Vancouver.
The deal gives ParcelPal access to more than 15,000 customers on the TokeIt platform and nearly 50 dispensaries partnered with TokeIt with which ParcelPal currently operates. According to the company, the average dispensary on the TokeIt Platform produces more than $250,000 per month.
More Deals Signal Additional Market Opportunities
As the marijuana industry evolves, new opportunities have come about. One of the bigger deals closed in 2019 was between ParcelPal (PTNYF) (PKG) and Yield Growth! The deals forms an alliance between the two companies for same-day and on-demand delivery, sale, of hemp-based cosmetics from Yield Growth’s subsidiary Urban Juve in Canada.
The New Market Reach Could Be Unparalleled
Urban Juve hemp products are currently sold in over 90 locations including well known pharmacy chains across North America, with a plan to expand that to 130 retail outlets in the near future.
Customers will be able to track their purchase in real time and have their product delivered to any location they specify. As time and regulations allow, ParcelPal’s cannabis network will continue to grow, with the goal of capturing a major piece of Canada’s $5.2 B legal cannabis market.
“ParcelPal is thrilled to be working an innovative company such as The Yield Growth’s Corp, which is addressing one of the fastest-growing subsegments of the $4.2 trillion wellness market with unique derived and cannabis infused products. This marks a milestone at ParcelPal, launching a new vertical with substantial growth potential. It’s also a unique opportunity to be at the forefront of an exciting new industry with our unique logistics solutions.”
Kelly Abbott, President and CEO, ParcelPal Technologies
New Opportunities Arise With Leadership
The company welcomed Ontario MP Parm Gill as an advisor to the Board of Directors.
Parm Gill is the current Member of Provincial Parliament for Milton. Prior to his work in public service, Parm was involved in several family businesses in the manufacturing and hospitality industries. Parm studied at the Ivey School of Business at Western University, earning his Master of Business Administration degree.
Before being elected to the Ontario Legislature in 2018, Parm was the Federal Member of Parliament for Brampton-Springdale from 2011-2015.
While serving as the MP in the Canadian House of Commons, Parm was appointed as the Parliamentary Secretary to the Minister of Veteran Affairs, and later, the Minister of International Trade. Throughout his tenure, Parm was a member of many committees including the Standing Committee of Public Safety and National Security, Health, Canadian Heritage, Veterans Affairs, and International Trade
An Industry Already Built For Big Buyouts
Amazon is often named as a potential suitor for a number of tech-based companies, especially for food delivery, where the Whole Foods acquisition might have been just the tip of the iceberg. In 2017, a study from the Food Marketing Institute (FMI) and The Nielsen Co. predicted that, by 2025, as many as 70% of U.S. consumers will be buying groceries online, and those purchases will total more than $100 billion. An update of the FMI/Nielsen report published last month, however, moved that timeframe up by three years to 2022.
FMI and Nielsen cited big acquisitions as key drivers accelerating the pace of change in the online food market.
The report calls out the $13.7 billion purchase of Whole Foods by Amazon.com Inc. in 2017, the 2016 acquisition of Jet.com by Walmart Inc. for $3.3 billion, the purchase of meal-kit delivery company Plated by Albertsons Cos. last fall (terms were not disclosed), and the acquisition of Shipt Inc. by Target late in 2017 for $550 million.
Currently, the FMI/Nielsen report says that 49% of U.S. consumers shop for consumer packaged goods (CPG)—the kinds of products typically found in grocery stores—online. And it’s not just Millennials who are shopping for food online. The report says that 61% of Millennials, 55% of Generation X, 41% of Baby Boomers, and 39% of those born before the Baby Boom reported having recently purchased a CPG product online.
These Are Just The Numbers From The United States!
The purpose of mentioning big figures like these isn’t to explain how big the US market for on-demand delivery has become; it’s to show how big it could become across other markets. With big buyouts from some of the major players in the business like WalMart, Albertsons, and Amazon, this industry is already built for big buyouts.
The Market Boom is Coming
The M&A strategy shows that this market isn’t one to ignore right now, and the real market boom may not even be here yet. Between 2016 and 2017, the amount that users are spending for ordering/booking on-demand service apps has only risen.
According to the data collected by the National Technology Readiness Survey in the U.S., it was estimated that total spending on the on-demand mobile app services would increase from $48 billion n 2016 to $75.7 billion in 2017—an increase amounting to 58%.
The segments of the on-demand startup market that have witnessed maximum growth, consist of housing items from $5 billion in ‘16 to $10.6 billion in ‘17; transportation, which moved from $6.8 billion in ‘16 to $14.2 billion in ‘17; and, lastly, the food delivery category, which shifted to $8.2 billion in 2017 from $3.9 billion in 2016.
Seeing this growing spending number, Rockbridge estimated that the number of on-demand mobile app startup consumers would reach 56 million by the end of 2018 and 93 million by the time we hit 2022.
The rise in awareness has brought in a rise in the perceived advantage that users are getting by using the on-demand services. The main advantages include the ability to find service online on an app (70%), the benefit of paying and tracking the progress of the delivery person on the app (62%), and, lastly, the perk that comes with being connected with another person in place of a business (52%).
Limited Options In the Public Markets Give Rise To Targeted Opportunities For Investors
It’s true that this market is exploding right in front of our eyes, but just as with the boom that the “Over The Top” entertainment industry saw with the advent of Netflix, right now there are a limited number of offerings available for investors to look at.
It is undeniable how on-demand is changing the world around us as we know it. No matter which business segment you belong to, chances are that someone in your industry will be thinking about investing in the on-demand market.
This un-altering demand for the on-demand services is not just the truth of the present day; the future has a similar story to share. The future of on-demand lies in a number of categories. According to a PwC report, the on-demand economy revenue, which was $14 billion in 2014, will reach $335 billion by the time we reach 2025.
ParcelPal (PTNYF) (PKG) could already be grabbing first mover advantage when it comes to taking on the global arena. Surely, there are already billions being invested in the startups of tomorrow, and as these companies “prepare,” ParcelPal is already entering into key verticals, aligning with major companies like Amazon, while also expanding the technology of their application to deliver a seamless customer experience for a country that is just beginning to find out what on-demand services are!
With the feverish pitch that the global on-demand industry is set to see, can you afford to miss out on something for which early adopters are already earmarking billions of dollars for massive future growth?
ParcelPal (PTNYF) (PKG) News:
April 4, 2019 – ParcelPal (PTNYF) (PKG) Announces Call-in Details for Quarterly Reporting Call to Take Place on May 17, 2019
Feb 27, 2019 – ParcelPal (PTNYF) (PKG) Welcomes Brian Storseth to the Board of Directors and Acting Chairman
Jan 29, 2019 – ParcelPal (PTNYF) (PKG) Announces Strategic Partnership With MADD Canada to Stop Impaired Driving
Jan 17, 2019 – ParcelPal (PTNYF) (PKG) Bringing Augmented Reality to Platform With NexTech AR Integration Deal
Disclaimer: MIDAM VENTURES LLC has been compensated $75,000 per month by a ParcelPal Technology, Inc. for a period beginning September 1, 2018 and ending February 1, 2019 to publicly disseminate information about (PTNYF/PKG) to publicly disseminate information about (PTNYF/PKG). Midam Ventures has been compensated $100,000 by Parcel Pal and has extended coverage to April 1, 2019. Midam Ventures has been compensated $100,000 by Parcel Pal and has extended coverage to May 1, 2019. Midam Ventures has been compensated $200,000 by Parcel Pal and has extended coverage to June 1, 2019. Midam Ventures has been compensated $200,000 by Parcel Pal and has extended coverage to July 1, 2019. We may buy or sell additional shares of (PTNYF/PKG) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. We own zero shares. Click Here For Full Disclaimer
Gold Prices Have Investors Scrambling & Analysts Clamoring For Junior Gold Stocks
Gold has long been a safe haven stock. But as the market turned toward tech, precious metal stocks took a back seat…until now. Could the timing of gold’s next bull run be perfect right now?
Let’s look at things that have historically helped gold prices skyrocket in the past:
- Geopolitical stress
- Declining interest rates
- A weaker dollar
- Global economic slowdowns
- Big accumulation by billionaires investors
Open a newspaper or read any headlines right now and you’ll likely see that all four boxes get checked on this list right now. The cheery on this golden sundae is that none of these things can be remedied overnight. What that means is that the bull market for gold could just be getting started.
But timing is important and technical levels for gold are beginning to show an eerily similar trend that they haven’t truly shown in nearly a decade:
The last time gold prices were at these levels, the entire sector exploded! And it wasn’t just any breakout move. Gold prices ran to all-time highs on a bull market move that lasted for months. Are we looking at gold’s next bull run?
The key to scoring big with gold stocks is to be ready before the big move comes and to be in front of the right gold opportunities. And historically speaking, some of the biggest returns have come from the junior stocks:
Roxgold investors who played the last big gold boom saw shares skyrocket from $0.38 to nearly $2.30… 497%
Investors who bought shares of gold company New Gold Inc. prior to the big gold market move, saw the stock trade below C$1.50 and road a wave to highs of more than C$14… 1,167%
Victoria Gold Corp moved from just $0.11 to highs of $1.55 during the last gold rush… 1,309%
Guyana Goldfields traded under $0.70 just as the last gold rush hit, with early investors that could have ridden that momentum to highs of $11.79… 1,609%
Early buyers of Wesdome Gold saw the stock at levels UNDER C$0.50 and had a chance to ride that to highs of nearly $6… 1,722%
And there are countless other examples of just how massive a gold price breakout can be for junior gold stocks and one junior gold mining stock may be on the verge of striking a major payload!
Roscan Gold Corporation (ROS.V): The Next Canadian Gold Stock To Watch For 2019
Right now analysts are screaming from the rafters about gold stocks and it isn’t just because the fundamental economics are pointing at a move in the precious metal. The price of gold bullion has now cracked a new 5-year high! All of this could be creating the perfect storm for another big move for gold stocks.
RosCan Gold Corporation (ROS.V) has already positioned itself in one of the most prolific gold regions in the world. Specifically, RosCan is currently in the process of assembling a sizeable land package in the Birimian Rocks of West Mali, the most productive greenstone gold belts on the continent.
Birmian rocks are major sources of gold and it just so happens that Mali is one of the largest producers of gold in Africa as it stands today. When it comes to mining, it’s Location, Location, and Location.
And RosCan Gold Corporation (ROS.V) is in one of the hottest regions on the planet. Africa holds 40% of the world’s gold reserves. Ghana, Burkina Faso, and Mali produce nearly twice what South Africa did in 2018.
Growth In West Africa Has Been Explosive!
Over the last decade, West Africa’s Senegal Mali fault zone has become a hotbed for mining activity. The region generated $1.2 billion in 2015 alone. Some analysts also speculate that junior mining companies may benefit greatly from the considerable upside of properties located close to mines that are owned by some of the world’s largest mining companies .
There could be real opportunity for investors in the handful of junior companies that are sitting on interesting properties within close proximity to the assets of multibillion-dollar market cap companies.
RosCan Gold Corporation (ROS.V) has amassed a significant land package, encompassing 271km2, through option agreements to acquire 100%-owned permits in the prolific gold prospective Birimian rocks of west Mali. Roscan believes these are high potential properties, as they are located in an area of existing gold deposits and multi-million-ounce producers. This includes B2 Gold’s Fekola Mine, which lies in a contiguous property to the west of its Kandiole project.
Prolific Gold Discoveries Signal Opportunity
Some of the largest gold miners are now looking to West Africa for potential. Because the region is so rich in gold, heads are turning and that could mean opportunities for mergers and acquisitions.
RosCan Gold Corporation (ROS.V) may be on the verge of something big. RosCan’s initial compilation of technical information of the Kandiole Project identified several areas of immediate interest.
According to the company, an initial exploration program consisting of prospecting, mapping and sampling of the entire land position with the objective of identifying areas for more detailed exploration, including drilling.
In addition, a program of detailed soil and termite sampling was completed in specific areas of the Mankouke and Moussala North permits, considered, in the short term, to be the most prospective. The initial sampling program on the Kandiole Project identified 13 artisanal mining areas that returned rock grab samples of more than 0.5 g/t gold with local highs exceeding 10 g/t gold at Niala.
These newly identified mining sites have not been evaluated in the past and as such represents new evaluation opportunities for RosCan Gold Corporation (ROS.V).
Roscan Gold reported positive assay results from both its diamond drilling and air-core (AC) drilling programs at its Kandiole Project in Mali, West Africa. The drilling program was completed during April to July of 2019 and was designed to test both the north and south extensions of the Mankouke gold discovery zone and many other strong termite and soil, gold anomalies.
|In hole ACMan 19-167||5.86 g/t Au over 26.0 m (incl. 9.44 g/t Au over 10.0 m)|
|In hole ACMan 19-168||3.74 g/t Au over 30.0 m (incl. 6.73 g/t Au over 6.0 m)|
|In hole DDH 19-04||8.63 g/t Au over 10.0 m (incl. 11.48 g/t Au over 7.0 m)|
|In hole DDH 19-03||6.53 g/t Au over 5.0 m (incl. 10.09 g/t Au over 3.0 m)|
|In hole DDH 19-03||5.56 g/t Au over 3.0 m (incl. 7.14 g/t Au over 2.0 m)|
|In hole DDH 19-08||3.45 g/t Au over 10.0 m (incl. 6.76 g/t Au over 3.0 m)|
“We are continuing to show thatwe have an excellent new gold discovery at Mankouke that appears to have strike and depth continuity. Our land package has great potential and we are extremely encouraged by the hits we are seeing on the Mankouke permit.“Greg Isenor, President and CEO of Roscan Gold
The New “Gold Coast” Could Mean Big M&A Opportunities For Junior Miners
According to Mining Intelligence, West Africa’s mining development pipeline could have real longevity. Roughly 33% of all assets, regardless of the commodity are in the production or construction stages, 45% of all projects undergoing economic assessment studies, and a whopping 74% of all exploration projects are focused on gold.
This focus on gold in the exploration stage indicates that the importance of gold in West Africa’s mining sector could only increase in the future, as new projects will enter the production phase. Some of the bigger players already sniffing around in this space include:
- Teranga Gold, B2Gold (Mali), a company with a market cap of over $400 Million
- Iamgold (Burkina Faso, Mali), a company with a market cap of over $2 billion
- Endeavour Mining (Burkina Faso, Mali, Côte d’Ivoire), a company with a market cap of nearly $2.5 Billion
- Semafo (Côte d’Ivoire), a company with a market cap of over $1.5 Billion
And this is just naming a few…
To some extent, all mining companies are worth the value of the gold in the ground that they own. The problem is that as they mine that metal they need to replenish it or risk having no resources left.
The gold mining industry is set for a “wave of mergers and acquisitions” as smaller miners seek to consolidate to capitalize on higher prices, according to Polyus . Smaller companies may be able to prospect for new ore deposits but larger ones will tend to have a hard time discovering large enough deposits to make a difference. Hence you could see larger companies deciding to buy smaller ones.
The world’s largest gold companies have been busy acquiring rivals this year, with Barrick Gold buying Randgold Resources in January and Newmont Mining acquiring Goldcorp in April.
“There will be numerous stocks…that will be bought by big companies,” says Don Coxe chairman of Chicago-based financial firm Coxe Advisors.
With gold prices on the rise, larger gold companies could run into higher production costs simply based on the size of the company and its overhead. As is typical with most industries of scale, smaller companies could stand to reap the rewards of having strong asset classes and prime location while also holding lower operating costs. Western Africa could be presenting new opportunities especially considering the prices of gold right now and RosCan Gold Corporation (ROS.V) is positioning itself in some of the most prolific regions.
Billionaires Are Already Starting To Pour Money Into Gold Stocks
When it comes to gold and gold stocks, most novices will hear about big money flowing from “Main Street.” But this usually comes well after Wall Street hedge funds have already piled in. So it’s important to read between the lines and sniff out early institutional bulls.
In recent months, some of the most elite investors have turned to precious metals like gold as a part of their overall investment strategies. Whether you like Trump or not you’ll most likely agree on one thing: he’s thrown a wrench into the U.S. political climate. It remains to be seen what comes of that, but the president’s actions so far have some billionaires expecting his disruptive political influence to spill over into the investing world even more.
That “pile in” we talked about may have quietly, already begun. Billionaire hedge fund manager and DoubleLine Capital founder, Jeffrey Gundlach said in a recent interview , “I am certainly long gold… Gold and commodities broadly should benefit this year.”
But he’s not alone either. Legendary investor Paul Tudor Jones said that gold is his favorite trade for the next year or two , “I think one of the best trades is gonna be gold. If I had to pick my favorite [bet] for the next 12 to 24 months, it’d probably be gold.” The yellow metal “has everything going for it,” he said, adding that if it can reach $1,400 an ounce, it will push to $1,700 “rather quickly.”
Other hedge fund managers, including Ray Dalio, David Einhorn, and John Paulson, have also started building gold positions. If billionaires like these own gold, this could be the sign that retail investors have been waiting for. With all of them citing market uncertainty driven by global economics, gold could be starting to sound like a really good idea.
As financial unrest continues across the globe, currency valuations sinking and major support from some of the worlds foremost billionaires prompting a gold play, the writing could already be on the walls.
Is This Perfect Timing For Junior Gold Stocks – Charts Don’t Lie
One of the best-known indexes of small resource stocks in the world is the TSX Venture Exchange. It doesn’t take a technical wiz to see patterns on a chart or what’s happened each time this index has hit a certain level…here we are, Now:
What will happen next? Well, as we said above, it comes down to timing. Let’s take this one step further and look at the price of gold over the years:
The precious metal has seen a cyclical trend over the last 20 years. The first 10 years saw the last long term bull market for gold. As it stands today, the market has been in a downtrend for almost 10 years after. That means investors aren’t “gifted” with “golden opportunities” regularly and being that this could be nearing the end of the latest 10-year cycle, the timing might be playing a big role considering the economic environment!
Remember the last mini bull run during the broader 10-year uptrend? That started at the tail end of 2008 and didn’t stop until well into 2011. Junior metals stocks exploded. The examples mentioned earlier were only a handful and those percentage moves were in the thousands.
Will You Be Ready For The Next Gold Rush?
The picture is even clearer. The climate for a gold boom is heating up in a big way and all the ingredients are in place that could give big reasons to be watching junior gold stocks right now. RosCan Gold (ROS.V) has staked its claim in one of the most prolific gold regions in the world. They are in the same region as some of the largest gold miners in the industry.
These are “early days” in its exploration program. RosCan Gold Corporation (ROS.V) property position is not only on the prolific Siribaya Structure which hosts the Siribaya, Kabaya, Seko and Mankouke discoveries but also covers many other gold anomalies and several other structures. With a significant land position of 100%-owned permits in an area of producing mines, this junior miner may soon hit the radar of gold bulls!
Tepid global economic data continues to suggest a bullish case for gold. Non-farm jobs figures, China PMI and the business climate for countries like Germany could point to a slowing economy. This would help the stance on safe-haven stocks. Furthermore, if the Fed sticks to a plan that would involve more rate cuts, there could be even brighter days ahead for the yellow metal.
“Growth still remains weak globally and we have geopolitical tension between the US and Iran. Additionally, $1,400 is a pretty strong support level for gold. We are still in a rate easing cycle right now. Overall factors are still supportive of higher gold prices.”Howie Lee, an economist at OCBC Bank in Singapore, to Reuters
This isn’t a secret anymore. With continued global financial uncertainty, a push for further decentralization of currencies, and the clear demand by the world’s biggest billionaires to shift investment into gold, what better time is there to find the next “undiscovered” junior gold company poised for huge growth potential in one of the worlds biggest gold producing regions?
RosCan Gold Corporation (ROS.V) has assembled a team of management with decades of experience in gold. Some have even been part of major buyouts by some of the world’s largest gold companies. With the recent progress that the company has seen from its drilling program, the fervent demand for safe-haven investment, and the stampede of gold billionaire bulls flooding into the market right now, it may be time to start looking at junior gold stocks before the Main Street rush opens the floodgates.
Top 5 Reasons To Have RosCan Gold (ROS.V) On You Gold Stock List
1. RosCan Gold (ROS.V) is in the process of assembling a sizeable land package in the Birimian Rocks of West Mali, the most productive greenstone gold belts on the continent.
2. RosCan Gold (ROS.V) has assembled a team of management with decades of experience in gold. Some have even been part of major buyouts by some of the world’s largest gold companies.
3. The rising price of gold has billionaire investors bullish on junior gold stocks specifically
4. The 20-year gold trend could be signaling a new bull market for gold
5. Geopolitical unrest and slowing global economies could ensure a strong argument for a longer-term bull trend for gold prices.
The Future Of Drug Delivery Has Biotech Investors Focusing On One Small Company
Over the last 10 years, biotech has been one of the best performing sectors in the entire market. It’s been for good reason too. A number of biotech stocks have produced life-changing returns because of their treatments and opportunities have only gotten bigger as time goes on.
But this is only the beginning as top analysts are saying that the industry’s best days may be far from over especially considering that the SPDR S&P Biotech ETF is up 22% this year alone .
With a wave of groundbreaking products in the pipeline, biotechnology could be poised to keep churning higher for the foreseeable future. But how can you get in on the ground floor of the next big wave in biotech?
Follow the money…
Cancer has become one of the biggest killers of the modern age. More than 600,000 Americans die of cancer each year, according to the American Cancer Society. And nearly 1.8 million new cases will be diagnosed this year in the U.S. To say that these figures have created a massive pool of opportunity for companies would be an understatement and because of this, novel treatments are being developed.
Since the most frequently used treatment for cancer right now is chemotherapy, patients may not be getting a treatment that is truly effective. In fact, many patients are told that chemo has a 50/50 shot of success. This leaves the door open for companies to jump on the potential of targeted treatments and novel delivery methods.
Investors can’t ignore the potential that has been created in this instance…but where should they look? The short answer is to look for companies working to treat acute cancers or ones that don’t have much of a mainstream therapy. The drug delivery platform being created by one small biotech company could greatly change the landscape for cancer treatment and beyond!
PharmaCyte Biotech (PMCB) Has Developed A Drug Delivery Platform That Could Be On The Verge Of A MAJOR FDA Event!
If you’re looking at PharmaCyte Biotech (PMCB) at this exact moment, you’re seeing it before the company begins clinical trials and just as it’s preparing to complete its Investigational New Drug application for the FDA. Whether you’re new to biotech stocks or a seasoned vet, you should understand how important milestones like this are for a company.
The United States Food and Drug Administration’s Investigational New Drug (IND) program is the means by which a pharmaceutical company obtains permission to start human clinical trials and to ship an experimental drug across state lines before a marketing application for the drug has been approved.
Right now, PharmaCyte Biotech (PMCB) is putting together the necessary material for its planned clinical trial for inoperable pancreatic cancer, one of the most deadly forms of cancer today. Just to give you an idea, pancreatic cancer, in general, has the highest death rate of all major cancers. Only 9% of people with this cancer will survive more than five years .
Could This Be The Technology Behind The Next Big Biotech Breakthrough?
Will PharmaCyte Biotech (PMCB) be considered the next supernova in biotech? Its drug delivery technology could change the way countless diseases could be treated and it starts with a “box.” Cell In A Box ® technology specifically, can be used as a platform upon which therapies for several types of cancer and even diabetes are being developed.
Essentially, PharmaCyte’s (PMCB) therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. This could mean that they’ve found a way to take a broad treatment (chemotherapy) and turn it into a targeted one.
But as smart investors, it can’t just be a “plan to do something,” and PharmaCyte (PMCB) knows this…
Case and point: PharmaCyte’s partner, Austrianova, has successfully encapsulated the live cells used in PharmaCyte’s therapy for its planned clinical trial in patients with locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC).
Those cells are now growing and dividing inside the Cell-in-a-Box® capsules, and could suggest that all of the pieces necessary to complete and submit the long overdue IND application to the FDA are falling into place for the company’s upcoming clinical trial in the treatment of LAPC. Adding to this, PharmaCyte’s partner, Austrianova, has constructed and equipped a cGMP-compliant facility in the Thai Science Park in Bangkok, Thailand, which will be used to encapsulate the live cells using the Cell-in-a-Box® technology.
PharmaCyte’s submission of an IND application is what has its shareholder’s attention, but it’s what an FDA approval of that application could mean for PharmaCyte (PMCB) that could garner the most attention. Once the FDA has approved the company’s IND application for Cell-in-a-Box® + low doses of ifosfamide to treat LAPC, the FDA’s approval will essentially permit PharmaCyte to open clinical activities throughout the country.
Why Is Timing So Important Right Now?
Timing is always important especially when dealing with the stock market. What may be more crucial is when we’re talking about the biotech sector. Whether it’s phase trials or things like an investigational new drug designation, events like this could act and have acted as serious catalysts for countless companies.
Here’s why an open IND is key to PharmaCyte (PMCB) realizing a number of benefits that include:
- Beginning the formal arrangements required to conduct its clinical trial in LAPC.
- Working towards the major milestone of enrolling the first patient in its clinical trial.
- Publishing that the technology behind its LAPC treatment has passed the incredibly difficult FDA screening process and met all of the FDA’s regulatory requirements.
- Building global exposure of PharmaCyte’s Cell-in-a-Box® technology.
- Paving the way for the development of treatments for multiple diseases including diabetes and a host of solid tumors.
But aside from this, timing is so important right now because an approved IND submission would mean clinical trials could begin 30 calendar days from the submission date of the IND!
The best part: the data obtained to date from the encapsulation parameters of the manufacturing process itself indicate that the encapsulation portion of the process is fault free and reproducible, which is a fundamental requirement of the FDA.
Could those looking at PharmaCyte Biotech (PMCB) at this exact moment be looking at a right place/right time scenario?
Well, as Dr. Hidalgo, Principal Investigator of PharmaCyte’s trial, says, “If the results are very positive, these results may pave the way for an accelerated approval process through one or more avenues afforded by the FDA.”
Do you understand how big of an addressable market this could be for PharmaCyte?
Cancer drug sales are on track to eclipse the $200 billion mark early in the next decade , thanks to an innovation bonanza that’s transformed oncology into the fastest-growing segment across the entire pharmaceutical industry.
Specifically, a recent report  by EvaluatePharma estimated that global cancer drug sales could rise at a blistering compound annual growth rate of 12% over the next five years. When you talk about timing, this could be that moment in time to be actively looking for “the curve” and how to be ahead of it before the sector realizes such immense growth!
Cancer Fighting Stocks Are Getting Bought Before Investors Can Get Their Hands On Them
The global market for cancer drugs is huge and big players are investing heavily to gain an edge in this increasingly competitive market. In many cases, the average investor hasn’t had a chance to look at game-changing biotech companies lately for the simple reason that pharmaceutical giants are hot on the acquisition trail.
Bristol-Myers, a pioneer in immunotherapy, is acquiring rival Celgene for $74 billion. On top of this, the latest headlines show that Merck is acquiring cancer drug developer Peloton Therapeutics for $1.05 billion. The announcement came at the same time that Peloton was preparing for its IPO!
Looking for more? Earlier this year, Eli Lilly bought Loxo Oncology for $8 billion. Pfizer’s deal to acquire Array Biopharma for $10.64 billion has been seen as a positive sign by investors for more deals as well. This could be just the tip of the iceberg for cancer-fighting stocks!
With PharmaCyte (PMCB) on the path of submitting and potentially gaining FDA approval of its investigational new drug application, there’s no telling which pharma companies could have this company on the radar.
We may have just uncovered a company set to take the stage for novel drug delivery.
Medical science hasn’t yet won the war on cancer, but it is scoring important victories in battles against many forms of the disease. Advances in new treatments have made cancer a hot investing theme over the past 18 months, helping to power fresh interest in biotechnology stocks. And the star power of people like Jeopardy’s Alex Trebek has put cancer treatment front and center after a very public diagnosis of stage 4 pancreatic cancer.
Major industry influencers are taking every chance they can to buy up smaller companies. The figures are becoming even more staggering as new therapies and phase trials materialize. PharmaCyte Biotech (PMCB) could be making a convincing argument to become one of the top biotech stocks to watch right now.
Not Just A Cancer Fighting Technology
This isn’t “just another cancer company.” PharmaCyte (PMCB) has developed a technology that could completely change the way cell therapies are conducted! Right now, the company isn’t just focused on cancer, they’ve also begun to apply Cell In A Box ® to other diseases like Diabetes.
Just like the method for cancer, PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell. But this time it will be the cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body.
The cell lines being studied are human liver cells, stem cells and beta islet cells. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they are designed to function as a “bio-artificial pancreas” for purposes of insulin production.
PharmaCyte has obtained from the University of Technology Sydney (UTS) in Australia an exclusive, worldwide license to use insulin-producing genetically engineered human liver cells developed by UTS to treat Type 1 diabetes and insulin-dependent Type 2 diabetes. These cells, named “Melligen,” have already been tested in mice and shown to produce insulin in direct proportion to the amount of glucose in their surroundings.
In fact, when Melligen cells were transplanted into immosuppressed diabetic mice, their blood glucose levels became normal. The Melligen cells reversed the diabetic condition.
Key Leadership With Proven Track Records
As with most biotechnology companies, management is crucial and PharmaCyte (PMCB) has built its leadership team around industry expertise:
Kenneth L. Waggoner serves as the Chief Executive Officer, President and General Counsel of PharmaCyte Biotech and is the Chairman of the Board. He has 50 years of experience in management, business, operations and law.
Mr. Waggoner’s career includes leadership and legal positions at Chevron as Vice President and General Counsel of Chevron’s global downstream business after Chevron’s acquisition of Texaco.
Dr. Gerald W. Crabtree is the Chief Operating Officer of PharmaCyte Biotech and a Board member. He has spent almost 50 years working in academic, biotech and pharmaceutical companies with the majority of that vast experience being in the development of drugs and treatments for cancer. He held tenure as Director of Project Planning and Management (Oncology and Immunology) at Bristol-Myers Squibb, one of the leading biotech firms in the world.
More importantly, Dr. Crabtree served as Project Manager for the development of the major anticancer agent, Taxol®, the “number one” drug under development at BMS at that time. Taxol® ultimately became a multi-billion dollar drug for BMS and is still widely used to treat a variety of cancers.
PharmaCyte’s Chief Medical Officer, Dr. Linda S. Sher is no stranger to leading trial investigations. Dr. Sher has participated in the surgery and management of more than 700 patients. She has been the Principal or Co-Principal Investigator for more than 50 clinical trials. Dr. Sher is also the Chief of the Division of Clinical Research for the Department of Surgery at USC where she oversees the implementation and conduct of clinical trials for the entire department, averaging between 50 and 70 studies at all times. She is also the Vice Chair of the USC Institutional Review Board.
Adding to this list is Dr. Matthias Löhr. He serves as the Chairman of the PharmaCyte Biotech Scientific Advisory Board. Dr. Löhr served as Principal Investigator for the Phase 1/2 and Phase 2 clinical trials of PharmaCyte Biotech’s pancreatic cancer treatment that were completed in the early 2000s.
Not only is he familiar with the Cell-in-a-Box® live-cell encapsulation technology that forms the core of PharmaCyte Biotech’s pancreatic cancer treatment, he has actually administered PharmaCyte Biotech’s treatment (the combination of Cell-in-a-Box® capsules with low doses of the well-known anticancer drug ifosfamide) in clinical trials in patients with advanced, inoperable pancreatic cancer.
The company also has a host of medical and scientific advisors, all of which have decades of experience in the biotech arena.
Biotech Breakthroughs Set The Stage For Big Potential Ahead
Consider the base case for pancreatic cancer treatment alone and PharmaCyte (PMCB) could pose a strong argument to take a seat at the table for leading innovation. GBI Research’s latest report, Frontier Pharma: Pancreatic Cancer – Identifying and Commercializing First-in-Class Innovation could shed considerable light on PharmaCyte’s Potential.
The report states that while the pancreatic cancer treatment pipeline contains 447 therapeutics in active development across all Phases (compared to 209 currently marketed products) almost 75% of therapies are in Phase I or earlier .
According to Joshua Libberton, Analyst for GBI Research, “It is clear that drug developers are seeking novel approaches to pancreatic cancer treatment that differ from the present market.”
Right now, PharmaCyte (PMCB) could be on the verge of a major FDA event and a potential catalyst to become the next big biotech stock to watch. This industry is experiencing remarkable innovation, and now the race is to get behind the next breakthrough.
PharmaCyte’s (PMCB) unique technology, stand-alone therapies and top tier leadership are just a few of the key points to consider in our opinion. Being that timing could play a major role, this may be a company to take a close look at heading into the second half of 2019.
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer
Stock Price Mid-Day Update
What a way to start the week. The markets are green right now and even ahead of all of the expected financial meetings this week, sentiment is high. That’s true too for the companies we talked about this morning. So let’s dive in and get everyone caught up to speed.
ParcelPal Technology Inc. (PKG.CN) (PTNYF) Jumps On Integration News
ParcelPal Technology Inc. (PKG.CN) (PTNYF) has been on the move for most of the month and the recent jump comes on the heels of this penny stock announcing integration on the Shopify platform. If you’re wondering, this is the same Shopify that trades publicly at OVER $300 a share!
Now the deal was first scooped by Benzinga and was later confirmed when ParcelPal formally announced the deal later in morning. Businesses of any kind, notably cannabis merchants will be able to integrate their Shopify eCommerce store nearly instantly to ParcelPal’s ecosystem.
These merchants will enable their customers to tap into ParcelPal’s network and have their products delivered in an hour or less. ParcelPal has begun this process with Choom and Kiaro. You can read more about the ParcelPal/Shopify News Here. Since June 3, ParcelPal is up by more than 35% and we, for one, will continue to bring more updates as we find them.
GT Biopharma, Inc. (GTBP) Consolidation Could Lead To More Excitement
GT Biopharma, Inc. (GTBP) continues to pick up the pace. Since we initiated coverage on the company, we’ve watch GTBP climb as much as 30% and as of today, it’s still up by roughly 12.5% in just over a week. We have seen a bit of consolidation to start this week but that could open the door to more excitement in June. The big focus for GTBP onlookers has been on its immunotherapy portfolio.
The bottom line here is that big money is pouring into cancer-focused companies specifically. The fact that as we write this, Pfizer is in the middle of an $11 billion dollar deal to buy a cancer therapy company should be even more proof of this focus.
To date, GT Biopharma has completed one dose escalation Phase I-II expansion clinical trial, and one fixed dose Phase I-II expansion clinical trial, which collectively enrolled a combined 43 patients. On the surface, the Phase I-II expansion clinical trial demonstrated greater than 50% of Evaluable patients receiving 60 mg/kg dose had a positive clinical response.
Two patients exhibited a Complete Remission with one patient currently disease-free at 50 months post-treatment. Additionally, five patients exhibited Stable Disease, cancers that are neither increasing nor decreasing in severity, with the longest response lasting 12 months post-treatment. In addition to this, the company’s therapy has also shown that it could target HIV infected cells in the University of Minnesota’s preclinical testing. Not only that but in specific tests, data showed that HIV-infected targets that express the HIV envelope on their surface could be eliminated. We’ve put together a full report on GTBP so click here for more info.
Liberty Defense Holdings, Ltd. (SCAN.V) Surges On German Deal
We brought this back to the attention of our members earlier last week and since then things have been quite exciting to say the least. Here’s why: Liberty Defense was trading at CAD$0.69 and today we’ve witnessed a big boom to highs of $0.85 after making another big MOU announcement. What was the news? Liberty Defense (SCAN.V) will be collaborating with FC Bayern München to beta test HEXWAVE. You can read the whole PR here.
This is what Bill Riker, CEO of Liberty Defense, said about this deal, “The reception to our HEXWAVE product has been fantastic and we are excited about working alongside FC Bayern Munich, a team that is a household name in both Europe and North America. Our ability to deploy in both indoor and outdoor settings, with covert and overt applications, sets us apart and has also been driving increasing interest from the market.”
Search Stock Price (StockPrice.com)
Featured4 months ago
Multi-Trillion Dollar Industry Providing Massive Opportunity in 2019 & Beyond
Cannabis3 months ago
Two Massive Growth Industries, One Choice for Investors
Biotechnology2 months ago
Big Investments Are Signaling The Green Light For A ‘Hot Market’ With Cancer-Fighting Stocks
Featured1 month ago
This New Technology Could Transform A Multi-Billion-Dollar Industry!
Cannabis2 months ago
A New Cannabis Trend That The Market Should Take Immediate Notice Of Is Here!
Biotechnology2 weeks ago
The Future Of Drug Delivery Has Biotech Investors Focusing On One Small Company
Featured4 months ago
Opportunity Ahead for This Healthcare Stock
Stock Market Breaking News2 months ago
Liberty Defense (SCAN.V) Signs MOU with the Utah Attorney General for Testing of HEXWAVE